This company listing is no longer active
Roche Holding Resultados de beneficios anteriores
Pasado controles de criterios 5/6
Los beneficios de Roche Holding han disminuido a una tasa media anual de -8.5%, mientras que en la industria Pharmaceuticals los beneficios disminuyeron en un 4.6% anualmente. Los ingresos han ido disminuyendo a una tasa media de 0.4% al año. La rentabilidad financiera de Roche Holding es de 36.4%, y sus márgenes netos son de 20.3%.
Información clave
-8.54%
Tasa de crecimiento de los beneficios
-6.83%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 16.33% |
| Tasa de crecimiento de los ingresos | -0.44% |
| Rentabilidad financiera | 36.43% |
| Margen neto | 20.33% |
| Próxima actualización de resultados | 23 Jul 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential
Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside
The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead
Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating
Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year
As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating
Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution
Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead
Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead
Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead
Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...Roche Holding will see a 4.2576% revenue growth shaking the market
### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025
Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.Desglose de ingresos y gastos
Cómo gana y gasta dinero Roche Holding. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 25 | 63,356 | 12,880 | 13,767 | 12,535 |
| 30 Sep 25 | 63,422 | 11,155 | 13,786 | 12,847 |
| 30 Jun 25 | 63,488 | 9,429 | 13,804 | 13,158 |
| 31 Mar 25 | 62,942 | 8,853 | 13,739 | 13,265 |
| 31 Dec 24 | 62,395 | 8,277 | 13,674 | 13,372 |
| 30 Sep 24 | 61,488 | 9,448 | 13,510 | 13,377 |
| 30 Jun 24 | 60,581 | 10,619 | 13,346 | 13,381 |
| 31 Mar 24 | 60,511 | 11,059 | 13,416 | 13,463 |
| 31 Dec 23 | 60,441 | 11,498 | 13,486 | 13,545 |
| 30 Sep 23 | 61,486 | 11,263 | 13,690 | 13,669 |
| 30 Jun 23 | 62,530 | 11,028 | 13,894 | 13,793 |
| 31 Mar 23 | 64,172 | 11,725 | 13,793 | 13,696 |
| 31 Dec 22 | 65,814 | 12,421 | 13,691 | 13,599 |
| 30 Sep 22 | 66,716 | 13,539 | 13,262 | 13,592 |
| 30 Jun 22 | 67,617 | 14,657 | 12,833 | 13,585 |
| 31 Mar 22 | 66,734 | 14,294 | 12,405 | 13,804 |
| 31 Dec 21 | 65,850 | 13,930 | 11,977 | 14,022 |
| 30 Sep 21 | 63,974 | 13,975 | 12,037 | 13,747 |
| 30 Jun 21 | 62,098 | 14,019 | 12,097 | 13,472 |
| 31 Mar 21 | 61,221 | 14,157 | 12,026 | 13,019 |
| 31 Dec 20 | 60,343 | 14,295 | 11,954 | 12,566 |
| 30 Sep 20 | 61,361 | 13,626 | 12,289 | 12,382 |
| 30 Jun 20 | 62,378 | 12,957 | 12,624 | 12,198 |
| 31 Mar 20 | 63,065 | 13,227 | 12,904 | 12,061 |
| 31 Dec 19 | 63,751 | 13,497 | 13,183 | 11,923 |
| 30 Sep 19 | 62,736 | 12,654 | 13,275 | 11,702 |
| 30 Jun 19 | 61,721 | 11,810 | 12,933 | 11,480 |
| 31 Mar 19 | 60,609 | 11,155 | 12,800 | 11,337 |
| 31 Dec 18 | 59,497 | 10,500 | 12,667 | 11,194 |
| 30 Sep 18 | 58,611 | 10,483 | 12,641 | 11,005 |
| 30 Jun 18 | 57,725 | 10,465 | 12,615 | 10,815 |
| 31 Mar 18 | 56,736 | 9,549 | 12,322 | 10,672 |
| 31 Dec 17 | 55,746 | 8,633 | 12,029 | 10,529 |
| 30 Sep 17 | 54,961 | 9,154 | 11,148 | 10,411 |
| 30 Jun 17 | 54,176 | 9,675 | 10,266 | 10,293 |
| 31 Mar 17 | 53,406 | 9,626 | 10,305 | 10,172 |
| 31 Dec 16 | 52,636 | 9,576 | 10,343 | 10,050 |
| 30 Sep 16 | 52,109 | 9,332 | 10,655 | 9,975 |
| 30 Jun 16 | 51,581 | 9,087 | 10,966 | 9,900 |
| 31 Mar 16 | 50,992 | 8,975 | 10,953 | 9,678 |
| 31 Dec 15 | 50,403 | 8,863 | 10,940 | 9,455 |
| 30 Sep 15 | 50,364 | 8,908 | 10,978 | 9,305 |
| 30 Jun 15 | 50,324 | 8,953 | 11,004 | 9,155 |
| 31 Mar 15 | 50,095 | 9,143 | 10,924 | 9,068 |
Ingresos de calidad: ROG tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (20.3%) de ROG son superiores a los del año pasado (13.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de ROG han disminuido en un 8.5% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de ROG en el último año (55.6%) supera su media de 5 años (-8.5% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de ROG en el último año (55.6%) superó al de la industria Pharmaceuticals 30.9%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (36.4%) de ROG se considera alta.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/03/16 22:05 |
| Precio de las acciones al final del día | 2026/03/16 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Roche Holding AG está cubierta por 44 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Mark Purcell | Barclays |